Atypical adenomatous hyperplasia of prostate lacks TMPRSS2-ERG gene fusion

American Journal of Surgical Pathology

Volumn 37, Issue 10, 2013, Pages 1550-1554

  Cheng, Liang ^a   Davidson, Darrell D ^a   MacLennan, Gregory T ^b   Lopez Beltran, Antonio ^c   Montironi, Rodolfo ^d   Wang, Mingsheng ^a   Tan, Puay Hoon ^e   Baldridge, Lee Ann ^a   Zhang, Shaobo ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CÓRDOBA   (Spain)

^d UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^e SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Atypical adenomatous hyperplasia (adenosis); Biomarkers; Cancer mimicker; Differential diagnosis; Prostate; TMPRSS2 ERG rearrangements

Indexed keywords

ONCOPROTEIN; TMPRSS2 ERG FUSION PROTEIN, HUMAN; TMPRSS2-ERG FUSION PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PATHOLOGY; PRECANCER; PROSTATE HYPERTROPHY;

ADULT; AGED; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; ONCOGENE PROTEINS, FUSION; PRECANCEROUS CONDITIONS; PROSTATIC HYPERPLASIA;

EID: 84884512887     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e318294e9bc     Document Type: Article

References (52)

1. Montironi R, Scarpelli M, Mazzucchelli R, et al. The spectrum of morphology in non-neoplastic prostate including cancer mimics. Histopathology. 2012;60:41-58.
2. Bostwick DG, Qian J. Atypical adenomatous hyperplasia of the prostate. Relationship with carcinoma in 217 whole-mount radical prostatectomies. Am J Surg Pathol. 1995;19:506-518.
3. Bostwick DG, Srigley J, Grignon D, et al. Atypical adenomatous hyperplasia of the prostate: morphologic criteria for its distinction from well-differentiated carcinoma. Hum Pathol. 1993;24:819-832.
4. Montironi R, Bartels PH, Hamilton PW, et al. Atypical adenomatous hyperplasia (adenosis) of the prostate: development of a Bayesian belief network for its distinction from well-differentiated adenocarcinoma. Hum Pathol. 1996;27:396-407.
5. Cheng L, Shan A, Cheville JC, et al. Atypical adenomatous hyperplasia of the prostate: a premalignant lesion? Cancer Res. 1998;58:389-391.
6. Bostwick DG, Cheng L. Overdiagnosis of prostatic adenocarcinoma. Semin Urol Oncol. 1999;17:199-205.
7. Gaudin PB, Epstein JI. Adenosis of the prostate. Histologic features in needle biopsy specimens. Am J Surg Pathol. 1995;19:737-747.
8. Gaudin PB, Epstein JI. Adenosis of the prostate. Histologic features in transurethral resection specimens. Am J Surg Pathol. 1994;18: 863-870.
9. Lotan TL, Epstein JI. Diffuse adenosis of the peripheral zone in prostate needle biopsy and prostatectomy specimens. Am J Surg Pathol. 2008;32:1360-1366.
10. Doll JA, Zhu X, Furman J, et al. Genetic analysis of prostatic atypical adenomatous hyperplasia (adenosis). Am J Pathol. 1999; 155:967-971.
11. Bostwick DG, Cheng L. Precursors of prostate cancer. Histopathology. 2012;60:4-27.
12. Mazzucchelli R, Scarpelli M, Barbisan F, et al. Immunohistochemical expression of prostate tumour overexpressed 1 (PTOV1) in atypical adenomatous hyperplasia (AAH) of the prostate: additional evidence linking AAH to adenocarcinoma. Cell Oncol. 2013;36: 37-42.
13. Montironi R, Mazzucchelli R, Lopez-Beltran A, et al. Mechanisms of disease: high-grade prostatic intraepithelial neoplasia and other proposed preneoplastic lesions in the prostate. Nat Clin Pract Urol. 2007;4:321-332.
14. Zhang C, Montironi R, MacLennan GT, et al. Is atypical adenomatous hyperplasia of the prostate a precursor lesion? Prostate. 2011;71:1746-1751.
15. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310:644-648.
16. Tomlins SA, Bjartell A, Chinnaiyan AM, et al. ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol. 2009;56:275-286.
17. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer. 2008;8:497-511.
18. Klezovitch O, Risk M, Coleman I, et al. A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci USA. 2008;105:2105-2110.
19. Andreoiu M, Cheng L.Multifocal prostate cancer: biologic, prognostic, and therapeutic implications. Hum Pathol. 2010;41:781-793.
20. Tomlins SA, Laxman B, Dhanasekaran SM, et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature. 2007;448:595-599.
21. Salagierski M, Schalken JA. Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion. J Urol. 2012;187:795-801.
22. Mani RS, Tomlins SA, Callahan K, et al. Induced chromosomal proximity and gene fusions in prostate cancer. Science. 2009;326:1230.
23. Dhani NC, Emmenegger U, Adams L, et al. Phase II study of cytarabine in men with docetaxel-refractory, castration-resistant prostate cancer with evaluation of TMPRSS2-ERG and SPINK1 as serum biomarkers. BJU Int. 2012;110:840-845.
24. Hermans KG, van Marion R, van Dekken H, et al. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Cancer Res. 2006;66: 10658-10663.
25. Bismar TA, Dolph M, Teng LH, et al. ERG protein expression reflects hormonal treatment response and is associated with Gleason score and prostate cancer specific mortality. Eur J Cancer. 2012; 48:538-546.
26. Chen Y, Sawyers CL. Coordinate transcriptional regulation by ERG and androgen receptor in fusion-positive prostate cancers. Cancer Cell. 2010;17:415-416.
27. Cai C, Wang H, He HH, et al. ERG induces androgen receptormediated regulation of SOX9 in prostate cancer. J Clin Invest. 2013;123:1109-1122.
28. Weischenfeldt J, Simon R, Feuerbach L, et al. Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell. 2013;23:159-170.
29. Tomlins SA, Laxman B, Varambally S, et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia. 2008;10:177-188.
30. Scheble VJ, Braun M, Beroukhim R, et al. ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod Pathol. 2010;23:1061-1067.
31. Mehra R, Tomlins SA, Shen R, et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol. 2007;20:538-544.
32. Attard G, Clark J, Ambroisine L, et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene. 2008;27:253-263.
33. Gao X, Li LY, Zhou FJ, et al. ERG rearrangement for predicting subsequent cancer diagnosis in high-grade prostatic intraepithelial neoplasia and lymph node metastasis. Clin Cancer Res. 2012;18: 4163-4172.
34. Cerveira N, Ribeiro FR, Peixoto A, et al. TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia. 2006;8:826-832.
35. Zhang S, Pavlovitz B, Tull J, et al. Detection of TMPRSS2 gene deletions and translocations in carcinoma, intraepithelial neoplasia, and normal epithelium of the prostate by direct fluorescence in situ hybridization. Diagn Mol Pathol. 2010;19:151-156.
36. Perner S, Mosquera JM, Demichelis F, et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol. 2007;31:882-888.
37. Mosquera JM, Perner S, Genega EM, et al. Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin Cancer Res. 2008; 14:3380-3385.
38. Mosquera JM,Mehra R, ReganMM, et al. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res. 2009;15:4706-4711.
39. Bostwick DG, Cheng L. Urologic Surgical Pathology. 2nd ed. St Louis, MO: Mosby/Elsevier; 2008.
40. Williamson SR, Zhang S, Yao JL, et al. ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin. Mod Pathol. 2011;24:1120-1127.
41. Svensson MA, LaFargue CJ, MacDonald TY, et al. Testing mutual exclusivity of ETS rearranged prostate cancer. Lab Invest. 2011; 91:404-412.
42. Bostwick DG, Algaba F, Amin MB, et al. Consensus statement on terminology: recommendation to use atypical adenomatous hyperplasia in place of adenosis of the prostate. Am J Surg Pathol. 1994; 18:1069-1070.
43. Lopez-Beltran A, Qian J, Montironi R, et al. Atypical adenomatous hyperplasia (adenosis) of the prostate: DNA ploidy analysis and immunophenotype. Int J Surg Pathol. 2005;13:167-173.
44. Qian J, Bostwick DG. The extent and zonal location of prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia: relationship with carcinoma in radical prostatectomy specimens. Pathol Res Pract. 1995;191:860-867.
45. Brawn PN. Adenosis of the prostate: a dysplastic lesion that can be confused with prostate adenocarcinoma. Cancer. 1982;49:826-833.
46. Algaba F, Trias I. Diagnostic limits in precursor lesions of prostatic cancer. Eur Urol. 1996;30:212-221.
47. Falzarano SM, Navas M, Simmerman K, et al. ERG rearrangement is present in a subset of transition zone prostatic tumors. Mod Pathol. 2011;23:1499-1506.
48. Guo CC, Zuo G, Cao D, et al. Prostate cancer of transition zone origin lacks TMPRSS2-ERG gene fusion. Mod Pathol. 2009;22:866-871.
49. Lotan TL, Toubaji A, Albadine R, et al. TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinomas. Mod Pathol. 2009;22:359-365.
50. Noel EE, Ragavan N, Walsh MJ, et al. Differential gene expression in the peripheral zone compared to the transition zone of the human prostate gland. Prostate Cancer Prostatic Dis. 2008;11:173-180.
51. Hoeks CM, Hambrock T, Yakar D, et al. Transition zone prostate cancer: detection and localization with 3-T multiparametric MR imaging. Radiology. 2013;266:207-217.
52. Pavelic J, Zeljko Z, Bosnar MH. Molecular genetic aspects of prostate transition zone lesions. Urology. 2003;62:607-613.